Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. It operates in two segments, Healthcare and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its lead drug candidate is CPI-613 (devimistat), currently under Phase III clinical study for the treatment of metastatic pancreatic cancer and acute myeloid leukemia. The company is also involved in developing Promitil, a molecule designed for the targeted delivery of mitomycin-C in a proprietary prodrug form, completed Phase 1B clinical studies; Folate-targeted Promitil (Promi-Fol) which is aimed at local treatment (intravesical) of superficial bladder cancer; and Promi-Dox, a highly potent dual drug liposome with MLP and doxorubicin targeting a potential basket of tumors. In addition, it engages in the development of surgical and procedural devices, including orthopedic arthroscopy instrumentation. Rafael Holdings, Inc. was incorporated in 2017 and is headquartered in Newark, New Jersey.
| 1.63 | |
| 1.67 | |
| - | |
| 1.68 | |
| 1.6 | |
| 1.29-2.27 | |
| 41 026 K | |
| 23 780 K | |
| 540 K | |
| 0.2558 | |
| 1.046 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Rafael Holdings, Inc. Company remains focused on generating shareholder value by advancing our portfolio and identifying attractive opportunities for strategic investments NEWARK, N.J., Dec. 14, 202...
Strong pace of enrollment continues in pivotal Phase 3 global study (TransportNPC™) evaluating Trappsol® Cyclo™ for Niemann-Pick Disease Type C1 ("NPC1") Merger with Applied Molecular Transport,...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
